Owen JS - Search Results

1

Development of therapeutic splice-switching oligonucleotides.

Disterer P, Kryczka A, Liu Y, Badi YE, Wong JJ, Owen JS, Khoo B. Disterer P, et al. Among authors: owen js. Hum Gene Ther. 2014 Jul;25(7):587-98. doi: 10.1089/hum.2013.234. Epub 2014 Jun 19. Hum Gene Ther. 2014. PMID: 24826963 Free PMC article. Review.

2

Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces LDL cholesterol in vivo.

Disterer P, Al-Shawi R, Ellmerich S, Waddington SN, Owen JS, Simons JP, Khoo B. Disterer P, et al. Among authors: owen js. Mol Ther. 2013 Mar;21(3):602-9. doi: 10.1038/mt.2012.264. Epub 2013 Jan 15. Mol Ther. 2013. PMID: 23319054 Free PMC article.

3

Validation of oligonucleotide-mediated gene editing.

Disterer P, Simons JP, Owen JS. Disterer P, et al. Among authors: owen js. Gene Ther. 2009 Jun;16(6):824-6. doi: 10.1038/gt.2009.32. Epub 2009 Apr 2. Gene Ther. 2009. PMID: 19340016

4

Use of internally nuclease-protected single-strand DNA oligonucleotides and silencing of the mismatch repair protein, MSH2, enhances the replication of corrected cells following gene editing.

Papaioannou I, Disterer P, Owen JS. Papaioannou I, et al. Among authors: owen js. J Gene Med. 2009 Mar;11(3):267-74. doi: 10.1002/jgm.1296. J Gene Med. 2009. PMID: 19153972

5

Oligonucleotide-mediated gene editing is underestimated in cells expressing mutated green fluorescent protein and is positively associated with target protein expression.

Disterer P, Papaioannou I, Evans VC, Simons JP, Owen JS. Disterer P, et al. Among authors: owen js. J Gene Med. 2012 Feb;14(2):109-19. doi: 10.1002/jgm.1639. J Gene Med. 2012. PMID: 22228477

6

Human apolipoprotein E expression from mouse skeletal muscle by electrotransfer of nonviral DNA (plasmid) and pseudotyped recombinant adeno-associated virus (AAV2/7).

Evans V, Foster H, Graham IR, Foster K, Athanasopoulos T, Simons JP, Dickson G, Owen JS. Evans V, et al. Among authors: owen js. Hum Gene Ther. 2008 Jun;19(6):569-78. doi: 10.1089/hum.2007.169. Hum Gene Ther. 2008. PMID: 18578629

7

Oligonucleotide-directed gene-editing technology: mechanisms and future prospects.

Papaioannou I, Simons JP, Owen JS. Papaioannou I, et al. Among authors: owen js. Expert Opin Biol Ther. 2012 Mar;12(3):329-42. doi: 10.1517/14712598.2012.660522. Epub 2012 Feb 10. Expert Opin Biol Ther. 2012. PMID: 22321001 Review.

8

Failure to generate atheroprotective apolipoprotein AI phenotypes using synthetic RNA/DNA oligonucleotides (chimeraplasts).

Manzano A, Mohri Z, Sperber G, Ogris M, Graham I, Dickson G, Owen JS. Manzano A, et al. Among authors: owen js. J Gene Med. 2003 Sep;5(9):795-802. doi: 10.1002/jgm.403. J Gene Med. 2003. PMID: 12950070

9

ApoE gene therapy to treat hyperlipidemia and atherosclerosis.

Harris JD, Evans V, Owen JS. Harris JD, et al. Among authors: owen js. Curr Opin Mol Ther. 2006 Aug;8(4):275-87. Curr Opin Mol Ther. 2006. PMID: 16955690 Review.

10

Efficient coexpression and secretion of anti-atherogenic human apolipoprotein AI and lecithin-cholesterol acyltransferase by cultured muscle cells using adeno-associated virus plasmid vectors.

Fan L, Drew J, Dunckley MG, Owen JS, Dickson G. Fan L, et al. Among authors: owen js. Gene Ther. 1998 Oct;5(10):1434-40. doi: 10.1038/sj.gt.3300746. Gene Ther. 1998. PMID: 9930350

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

239 results

Search Page